

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



## Probiotics for Autoimmune Diseases: Is There a Benefit?

Öner Özdemir<sup>1</sup> and Azize Yasemin Göksu-Erol<sup>2,3</sup>

<sup>1</sup>*Department of Pediatrics, Division of Allergy / Immunology,  
İstanbul Medeniyet University,  
Göztepe Research and Training Hospital, Istanbul*

<sup>2</sup>*Suleyman Demirel University Medical School,  
Dept. of Medical Genetics; Isparta*

<sup>3</sup>*Afyonkocatepe University Medical School,  
Dept. of Histology&Embryology; Afyonkarahisar,  
Turkey*

### 1. Introduction

Experimental and clinical trials of probiotic use as capable preventive and therapeutic strategy in different diseases varying from allergic to autoimmune disease have recently reported. Probiotics are used in allergic disease, which have shown to be beneficial in some patients with atopic dermatitis and allergic rhinitis [1]. Based on the hygiene hypothesis, it has been theorized that changes in human intestinal microflora in developed societies cause an increase in the prevalence of autoimmune disease (AD) besides allergies [2]. Regulation of intestinal microflora composition by probiotics may offer the possibility to influence the development of mucosal/systemic immunity as well as ADs. In this article we will consider the etiology of AD and its relation to gut and environmental microbiota (hygiene) before discussing the mechanisms of probiotic effect and the beneficial effects that they may confer to individuals with AD.

### 2. Brief pathophysiology of AD: What causes an AD?

The immune system normally acts to ensure tolerance to 'self', but a breakdown in the tolerogenic pathways has been hypothesized to lead to AD that may result from loss of tolerance to self antigens in general. A breakdown in the tolerogenic pathways can also lead to other so-called inflammatory diseases e.g. atopic and inflammatory bowel disease (IBD). Allergic disease may result from loss of tolerance to food and environmental antigens; IBD may result from loss of tolerance to commensal bacteria within the intestinal tract. The main characteristics of IBD and AD are tissue destruction and functional impairment as a consequence of immunologically mediated mechanisms which are principally the same as those functioning against dangerous (pathogenic) infections. In case of ADs, a major effort was done in understanding pathogenetic mechanisms leading to the loss of tolerance to self components (autoantigens). Despite the fact that target antigens and the genetic basis of several ADs are now better understood, the initial events leading to a loss of tolerance

towards self components remain unknown. One of the most attractive explanations for autoimmune phenomena has always centered on various infections as possible natural events capable of initiating the process in genetically predisposed individuals.

The most accepted conventional hypothesis explaining how infectious components cause autoimmunity is based on the concept of cross-reactivity, "molecular mimicry". This hypothesis assumes a similarity between the epitopes of an autoantigen present in the afflicted organism and the epitopes in the environmental antigen. The latter may consist of a microorganism or another external antigen that causes the autoimmune response. The other hypotheses in the AD pathogenesis such as hygiene-old friends- hypothesis, bystander immunoregulation and T regulatory cell (Treg) defects are briefly discussed below as well.

Because of our long association with environmental organisms (old friends), they are recognized by the innate immune system as harmless or, in the case of some helminths, treated as "friends" because a response would merely lead to immunopathology [2]. Therefore, rather than priming aggressive immune responses, these organisms prime immunoregulation. They do it by inducing an unusual pattern of maturation of dendritic cells (DC) such that these retain the ability to drive Treg. Toll-like receptor 2 (TLR2) may be involved for helminths and TLR9 for lactobacilli. It is interesting that polymorphisms of NOD2 (an intracellular receptor for bacterial peptidoglycan) are linked to increased susceptibility to both Crohn's disease and asthma [3]. Thus an extension of the "hygiene" mechanism suggests that in an environment that less actively primes Treg activity, immunoregulatory disorders will occur first in those individuals whose innate immune systems are least efficient at driving Treg.

The increased regulatory dendritic cells (DCreg) and Treg induced by "old friends" then lead to two immunoregulatory mechanisms mediated in part by release of IL-10 and TGF- $\beta$ . Firstly, continuing exposure to "old friends" will cause continuous background activation of Treg specific for the "old friends" themselves, resulting in a constant background of "bystander suppression" [4]. This mechanism has been demonstrated in a model of colitis. Secondly, DCreg inevitably sample self and gut contents and so induce Treg specific for the target antigens of the groups of chronic inflammatory disorder. These mechanisms may be aborted when there are legitimate "danger" signals. For example, Treg function can be turned off by appropriate "danger signals" in vitro [5].

The unifying hypothesis explaining the simultaneous increase in T helper type 2 (Th2)-mediated allergies and Th1-mediated autoimmunity is that modern living conditions can lead to defective maturation of Treg and regulatory antigen presenting cell or DCreg [6]. Therefore, rather than Th1/Th2 balance, the crucial factor is likely to be the effector T cells/Treg balance. Thus diminished immunoregulation can lead to inappropriate immune responses to allergens, gut contents, or self. In the absence of optimal levels of immunoregulation, the individual may develop a Th1-/Th2-mediated inflammatory disorder, depending on his/her own particular Th1/Th2 bias, immunological history, and genetic background. Evidence to confirm this hypothesis has come from studies of allergic disorders, MS and autoimmune polyglandular syndromes [6].

### **3. Any role for hygiene (environmental microbiota) in AD development?**

According to the old 'hygiene (old friends) hypothesis', the decreasing incidence of infections in developed and developing countries is at the origin of the increasing incidence

of allergic diseases [7]. New practices, introduced as a result of industrialization, such as childbirth by surgical delivery, ingestion of pasteurized food, cleaner homes, and indiscriminate use of antibiotics and so on, have led in recent years to the replacement of probiotics by other microorganisms that are not as well adapted to the microenvironments of the human body. The hygiene hypothesis is based upon epidemiological data, particularly migration studies, showing that subjects migrating from a low-incidence of infections to a high-incidence country acquire the allergic and immune disorders with a high incidence at the first generation as well. Therefore, it was possible to extend the old hypothesis from the field of allergy, where it was formulated, to those of ADs such as T1D or multiple sclerosis (MS) [7,8]. However, some data and others showing a correlation between high AD incidence and high socio-economic level do not prove a causal link between infections and immune disorders. Part of the increased incidence of these diseases may be somewhat attributed to better diagnosis or improved access to medical facilities in economically developed countries. However, this cannot explain the marked increase in immunological disorder prevalence that has occurred over such a short period of time in those countries, particularly for diseases which can be diagnosed easily, such as T1D or MS.

Proof of principle of the hygiene hypothesis is supported by animal models and to a lesser degree by intervention trials in humans. The incidence of spontaneous T1D is directly correlated with the sanitary conditions of the animal facilities, for both the non-obese diabetic (NOD) mouse and the bio-breeding diabetes-prone (BBDP) rat: the lower the infectious burden, the higher the disease incidence [8,9,10]. Diabetes has a very low incidence and may even be absent in NOD mice bred in 'conventional' facilities, whereas the incidence is close to 100% in female mice bred in specific pathogen-free conditions [11]. Furthermore, BBDP rats subject to Cesarean derivation have been noted to develop accelerated disease due to lack of contamination with microbiota in birth canal [12]. Taken together, these data open new therapeutic perspectives in the prevention of allergic and ADs.

#### 4 Intestinal microbiota and their role in ADs?

Based on hygiene hypothesis, the sudden change in human intestinal microflora may importantly contribute to the rise in the incidence of ADs, observed in the last half a 20<sup>th</sup> century [7]. More than 17 bacterial families encompassing 500 different microbial species can be found in human adults. These commensal bacteria regulate a myriad of host processes and provide several nutrients to their host and their symbionts within the microbial community. In healthy individuals these relationships are thought to occur in equilibrium. However, disruption of this equilibrium may contribute to a variety of conditions including AD, IBD and atopic disease [13]. This connection is gaining credibility as associations between gut microbiota and either the risk for or presence of a variety of specific human diseases is demonstrated.

Accordingly, the pathogenesis of ADs has been recently thought to involve an interaction between genetically determined host susceptibility, the enteric microbiota and dysregulated immune response. Interactions between the intestinal environment, barrier function, and immune system have been shown to have a major impact in the rate of autoimmunity development. Disruption of intestinal barrier function and aberrant mucosal immune activation has been implicated in a variety of diseases within and outside of the gastrointestinal tract [2,9]. The penetration of gut bacterial antigens into lymphoid tissues is

one of the suggested initial factors leading to a loss of tolerance towards self components in genetically predisposed individuals. With this model in mind, recent studies have shown a link between diet, composition of intestinal microbiota, and pathogenesis of ADs. Furthermore, this new paradigm subverts traditional theories underlying autoimmunity development, which are mainly based on molecular mimicry, and suggests that the autoimmune process can be arrested if the interplay between genes and environmental triggers is prevented by re-establishing intestinal barrier function [14].

A hypothesis previously has been proposed involving a trio of interacting factors that may create a “perfect environment” for ADs such as type 1 diabetes (T1D) development. These factors include (i) an aberrant intestinal microbiota, (ii) a ‘leaky’ intestinal mucosal barrier, and (iii) altered intestinal immune responsiveness [15]. In support of this model, modulation of T1D pathogenesis in animal models has proved successful through early intervention with a variety of dietary alterations. Indeed, the administration of a hydrolyzed casein diet or the administration of antibiotics has strengthened the hypothesis that an aberrant microbiota could accelerate disease development. More importantly, this is not a phenomenon that occurs only in rodent models of diabetes, as very recent studies have noted that humans with a propensity to develop T1D as well as other ADs possess an abnormal intestinal barrier; the so called “leaky gut” [8,14]. Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to nonself-antigens. Other modulators of tight junction proteins such as certain probiotics may also play a role in modulation of “intestinal leakiness” [8,9,13,15].

## 5. What are probiotics?

Probiotics are usually isolated from the commensal microflora that inhabits the skin and mucosas. And they represent the species of viable microorganisms (bacteria or yeasts) that have a clear beneficial effect on the health of the host thru establishing a true symbiotic relationship with humans for the longest time. Probiotic is derived from the Greek word meaning “supporting or favoring life”. The works of Metchnikoff and Tissier were the first to make scientific suggestions about the probiotic use of bacteria, even if the word “probiotic” was not coined until 1960, to name substances produced by microorganisms which promoted the growth of other microorganisms [16].

Probiotics are first described as selective nonpathogenic living microorganisms or components of bacteria in food supplements, including some commensal bacterial flora, which have beneficial effects on host health and disease prevention and/or treatment [17]. However, experts have debated how to define probiotics. One widely used definition, developed by the World Health Organization and the Food and Agriculture Organization of the United Nations, is that probiotics are “live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host.” Probiotics are also defined as ‘mono- or mixed cultures of live microorganisms which, when applied to animal or man, beneficially affect the host by improving the properties of the indigenous microflora’ [16].

A probiotic bacterium is required to fulfill certain criteria to be of benefit [1]. These include being of human origin and having generally regarded as safe status, acid and bile stability, adherence to intestinal cells, persistence for some time in the gut, ability to produce



antimicrobial substances, antagonism against pathogenic bacteria, and ability to modulate the immune response. Probiotic activity has been found to be associated with *Lactobacilli*, *Lactococci*, *Bifidobacteria* (*longum*, *infantis*), *Streptococcus* (*thermophilus*), *Enterococcus* (*faecium*), nonpathogenic *E. coli* (Nissle 1917), *Bacillus coagulans* and *Saccharomyces* strains (*boulardii* and *cerevisiae*) [1,17]. The most popular lactic acid bacteria are members of the genera *Lactobacilli* and *Lactococci*, which have a long history of safe use. *Lactobacillus acidophilus* is the most well-known probiotic and one of the most important for the health of the small intestine. Other examples of probiotics are *Lactobacillus rhamnosus* GG (LGG), *Lactobacillus gasseri*, *Lactobacillus fermentum*, *Lactobacillus salivarius*, *Bifidobacterium bifidum* and *Streptococcus* strains include *cremoris*, *faecium* and *infantis*.

The number of commercially available products that are supplemented with probiotics is rising. Dairy products that contain probiotics are sold in every supermarket and probiotic food supplements (for example; capsules, tablets, and powders) can be purchased in pharmacies or via the internet. For infants, infant formulas containing probiotics are also currently available. Live probiotic cultures are available in fermented dairy products and probiotic fortified foods. Examples of foods containing live probiotics are yogurt, fermented and unfermented milk, miso, tempeh, and some juices and soy beverages. However, tablets, capsules, powders and sachets containing the bacteria in freeze dried form are also available.

## 6. A cultural product related to probiotics: Yogurt (Yoğurt)

Increasing interest has also been paid to the beneficial functions of *Lactobacilli* in addition to their importance in the preparation process of fermented foods such as yogurt and cheese. Here, the reason for selecting yogurt as a probiotic food was several-fold. It can be produced in a sustainable manner locally and therefore doesn't rely on importation, and it provides nutrition and is an excellent carrier for probiotic organisms.

Fermented foods, particularly dairy products like yogurt, have been consumed for centuries in some cultures including Turkish. A similar health effect is also observed for lactose fermenting starter bacteria such as *Lactobacillus delbrueckii* ssp. *bulgaricus* and *Streptococcus thermophilus* in fermented milk products like yogurt. However, these traditional starters are not considered probiotics by some researchers since they lack the ability to proliferate in the intestine [16]. Therefore probiotic yogurt including different probiotic strains (*Lactobacilli* and/or *Bifidobacteria*) than standard one has been produced and become popular in recent literature. Probiotic yogurt includes a probiotic strain or multistrain probiotics that has been shown to have beneficial effects on the health of the host with HIV/AIDS and diarrhea [18]. Traditional yogurt was compared in a study with probiotic yogurt in non-inflammatory acute gastroenteritis. Acute non-inflammatory gastroenteritis improvement is accelerated by probiotic yogurt consumption [19]. Probiotic yogurt intake was associated with significant anti-inflammatory effects that paralleled the expansion of peripheral pool of putative T(reg) cells in IBD patients and with few effects in controls [20].

Yogurt contains viable bacteria culture including *Streptococcus thermophilus* and *Lactobacillus delbrueckii* sp. *bulgaricus* [1]. Although these cultures clearly fulfill the current concept of probiotics, only a small number of these bacteria have been studied. Yet some specifically have been shown to have a probiotic effect [1,21,22]. Health effects of traditional (standard) yogurt will not be reviewed in detail here; several reviews have already been published on

this topic [1,16,21]. Yoğurt has been shown to be successful for reducing the duration of symptoms in acute non-bloody diarrhea in 6-24-month-old hospitalized infants [23]. Yoğurt feeding was associated with a clinically relevant decrease in stool frequency and duration of diarrhea in children who have reducing sugars in stools [24]. Positive changes in lipid profile were observed in both yoğurt groups [25].

Although there is well-known assumption of longer human life in the cultures consuming frequently yoğurt, the neat probiotic effect of yoğurt on the frequency of ADs is unknown.

## 7. Can probiotics really prevent and/or treat any type of ADs?

The new version of 'hygiene hypothesis' proposes that reduced exposure to environmental and/or enteric stimuli, including microbes, underlies the rising incidence of childhood ADs [7,15,26]. This hypothesis is supported by data that highlight the importance of infant exposure to environmental microbes for appropriate development of the immune system. This might explain the observation that administration of microbes or their components inhibits AD in animals such as T1D, as mentioned above [2,13-15]. These findings raise the possibility of using live, nonpathogenic microbes (for example, probiotics) or microbial components to modulate or 're-educate' the immune system.

For some time now, microbial agents have been implicated in the etiology of ADs, including insulin dependent diabetes mellitus (T1D). Recent studies, however, have revealed that exposure of genetically diabetes-susceptible animals to certain microbes or microbial agents at an early age prevent the induction and progression of disease. This suggests that microbes may act to modulate the immunological status or immune repertoire of an individual genetically programmed for T1D away from an autoimmune response [27]. Immunization with microbial agents at an early age may offer an important new direction for the immunotherapy of T1D [10,28]. The protective effect of a probiotic and a bacterial extract was reported on the onset of diabetes in NOD mice.

Similarly, there is an increasing amount of data showing that intestinal microbiota changes could contribute to the modulation of immune disorders but evidence is still slim, except in IBD. The case of probiotics in IBD is more complex because of the possible local anti-inflammatory effect, which could explain the relief of symptoms without changes in disease progression, as implicated in the hygiene hypothesis. Following a number of uncontrolled studies in a small cohort of 14 pediatric patients with newly diagnosed ulcerative colitis (UC), probiotic treatment induced a significant rate of remission compared to the control group and a lower relapse rate [29].

### *Supposed Mechanisms of Probiotics` Effects in the Prevention/Treatment of ADs*

Some supposed mechanisms of probiotics` effects in the development of autoimmunity defined in the recent literature are discussed below (as summarized and shown in figure 1).

#### 1. Immunoregulation by TGF- $\beta$ -bearing Treg cells

CD4+/CD25+ - Tregs have shown to be pivotal players in the maintenance of immune tolerance. Their role in the prevention of autoimmunity in animal models and evidence for disturbed or dysfunction of Tregs have also been observed in patients with different ADs, including MS [6]. Recent studies provided evidence that one effect of probiotics may involve induction of differentiation of IL-10-dependent, TGF- $\beta$ -bearing Tregs [6]. They also can

suppress immune responses distinct from responses against the antigen in question, here antigens expressed by infectious agents (a phenomenon called bystander suppression).




Fig. 1. This figure illustrates some supposed mechanism of probiotic effects on the development of autoimmunity and autoimmune diseases. Probiotics seem to have a regulatory effect on Treg, Th1, Th17, intestinal cells and splenocytes.

2. Development of tolerogenic DCs

Lctb reuteri / casei have been also shown to prime monocyte-derived DCs through the C-type lectin DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) to drive the development of Tregs [30]. These Tregs produce increased levels of IL-10 and are capable of inhibiting the proliferation of bystander T-cells. This study suggests that the targeting of DC-SIGN by certain probiotic bacteria might explain their beneficial effect in the treatment of a number of inflammatory diseases, including AD [1].

3. Reducing proinflammatory cytokines through Th17 cells

Th17 has been also shown as pathogenic cells in some ADs such as experimental autoimmune encephalomyelitis (EAE) and arthritis [31]. Suppression of this newly discovered subset of T cells by probiotics might explain effects observed in different experimental models that all involve inflammatory responses, i.e. colitis. For instance; Lctb casei suppressed experimental arthritis by reducing proinflammatory cytokines released from Th17 cells.

4. Stimulating Th1 cells

Although there are still some studies showing no significant effects of probiotics on either Th1/Th2 cell responses, certain strains of Lctb and Bfdbm modulate the production of



cytokines, and may divert the immune system in a regulatory or tolerant mode. Changes in cytokine profile induced by probiotics may be probiotic strain- or site-specific and dependent on the experimental system used. For instance, *Lctb reuteri* induced proinflammatory and Th1 cytokines; and *Bfdbm bifidum/infantis* and *Lctb lactis* reduced Th2 cytokines and acted as potent inducers of IL-10 production [32].

#### 5. Probiotic regulation in intestinal epithelium and upregulation of host immune responses to defend against infection

Probiotics compete with non-commensal bacteria and eliminate them by secreting antimicrobial products, increase the production of antibodies and macrophage activity and contribute to the appropriate host nutrition by producing some vitamins and by breaking down undigested molecules. These characteristics argue in favor of a symbiotic relationship between humans and probiotics [1]. Probiotic administration in humans and animals has also been shown to be beneficial in the treatment and prevention of intestinal infections and to reduce mucosal inflammation. Their ability to deviate tissue cytokine secretion from a pro-inflammatory to an anti-inflammatory profile has been specifically described. This effect probably results from the ability of probiotics to adhere to mucosal surfaces and inhibit the attachment of other pathogenic bacteria, to secrete factors that enhance barrier integrity, and to modulate cells of the immune system [33].

#### 6. Anti-inflammatory effect of probiotics

The anti-inflammatory effect of probiotics has been attributed to increased production of IL-10 by immune cells in the lamina propria, Peyer's patches and the spleen of treated animals [34]. Moreover, a decrease in the secretion of pro-inflammatory cytokines, IFN- $\gamma$ , TNF- $\alpha$  and IL-12 has been demonstrated [33].

#### 7. Maturing gut barrier

Recent data indicate that commensal intestinal microbiota represents a major modulator of intestinal homeostasis. Dysregulation of the symbiotic interaction between intestinal microbiota and the mucosa may result in a pathological condition with potential clinical repercussions. For instance, it is shown that mice reared in germ-free conditions have an underdeveloped immune system and have no oral tolerance. In contrast, pathogen-free mice are capable of reconstituting the bacterial flora with *Bfdbm* and tolerance development. In addition to providing maturational signals for the gut-associated lymphoid tissue, probiotics balance the generation of pro- and anti-inflammatory cytokines in the gut. After probiotic consumption, decrease in fecal  $\alpha$ -1 antitrypsin, serum TNF- $\alpha$ , and changes in TGF- $\beta$  and other cytokines point to down-regulation of inflammatory mediators [33]. Furthermore, probiotic bacteria may counteract the inflammatory process by stabilizing the gut microbial environment and the permeability barrier of the intestine, and by enhancing the degradation of enteral antigens and altering their immunogenicity. This gut-stabilizing effect of probiotics could be explained by the improvement by probiotics of the immunological barrier of the intestine through intestinal IgA responses, specifically [1,35].

#### 8. Systemic TLR stimulation via non-antigenic ligands

A number of experiments indicate that infectious agents can promote protection from ADs through mechanisms independent of their constitutive antigens, leading to stimulation of

non-antigen specific receptors such as TLRs. A family of pattern recognition receptors such as TLRs on gut lymphoid and epithelial cells mediates innate immune responses to bacterial molecular patterns and, thereby, orchestrates acquired immunity. An observation made for TLR-2/-3/-4/-7 and -9 that TLR stimulation could prevent the onset of T1D in NOD mice [9,10,36].

Although the beneficial effects of probiotics on wide variety of diseases have been shown, little is known about how probiotics modulate the immune system and autoimmunity development. Currently, only limited publications are available mentioning the effects of probiotics on ADs in rodent models or human. Therefore, it was important to explore the effect of human probiotics in various autoimmune experimental and clinical disease models. Here, firstly experimental and later clinical studies of probiotics in different ADs under the recent literature gathered from Medline and Pubmed are discussed.

8. Animal experimental models and human clinical trials describing supposed effects of probiotics in ADs

Benefits of probiotic use in firstly animal experimental and later human clinical models of ADs including arthritis, T1D, EAE and IBD will be mentioned correspondingly in this assessment. Presumed favorable effects of probiotics in various ADs reviewed in this article are also shown in table 1 and 2.

Disease model	Probiotics	Assessment	Outcome	Ref.
<i>Animal Experimental Autoimmune Encephalomyelitis Models</i>				
EAE	LcS	↑IL-10, ↑TGF-β	↓disease activity	55,56
EAE	LcS	↑ Th1 cytokines	↑ disease activity	55,56
EAE	Lctb reuteri	↑ proinflammatory cytokines	↑ disease activity	32,54
EAE	LcS, BbY	myelin basic protein	Ø disease activity	56
EAE	Lctb casei 393	↑ IL-10, ↑TGF-β	↓disease activity	55,56
EAE	Bfdbm animalis	↑Tregs, ↓ immune parameters, ↑ body weight gain,	↓disease activity	57
EAE	Lctb casei	↑ immunoregulatory cytokines	↓disease activity	55,56
EAE	Lctb paracasei	↓ proinflammatory cytokines, ↑ Tregs dependent on IL-10	↓disease activity	55,58
EAE	Lacto-mix	↑ Tregs, ↑IL-4, ↑IL-10, ↑TGF- β1	↓disease activity	55,58
<i>Animal Experimental Inflammatory Bowel Disease Models</i>				
DSS colitis	VSL#3	inflammation	↓disease activity	66
DSS colitis	E. coli Nissle 1917	inflammation	↓disease activity	66

Disease model	Probiotics	Assessment	Outcome	Ref.
IL-10-/- mice colitis	Lctb salivarius	↓IFN-γ	↓disease activity	62,63
IL-10-/- mice colitis	Bfdbm infantis	↓IFN-γ	↓disease activity	62,64
IL-10-/- mice colitis	Lctb reuteri	inflammation	↓disease activity	61
IL-10-/- mice colitis	Lctb plantarum	↓IL-12, ↓IFN-γ	↓disease activity	60
Animal Experimental Diabetes Mellitus Models				
T1D	Lctb casei	↓ β-cell destruction, ↓IFN-γ, ↑IL-2	↓ disease activity	51,52
T1D	LcS	↓ β-cell destruction, ↓autoreactive CD8+ T-cells	↓ disease activity	51,52
T1D	VSL#3	↓ insulinitis and β-cell destruction, ↑IL-10, ↑IFN-γ	↓ disease activity	50
T1D	Lctb johnsonii	modify gut microbiota:↓ pro-inflammatory cytokine, ↓IFN-γ, ↓ iNOS and ↑Cox2, ↑claudin (the tight junction protein)	↓ disease activity	48,49
T1D	Lctb reuteri	modify gut microbiota	↓ disease activity	51,52
Animal Experimental Arthritis Models				
CIA	LcS	↓CII-induced IgG2a/2b, ↓IFN-γ production by spleen cells	↓ disease activity	41
CIA	Lctb casei	↓proinflammatory cytokines, ↓T-cell proliferation, ↑IL-10, ↓CII-induced IgG2a/2b, ↑Foxp3+/CD4+-T cells	↓paw swelling, ↓disease activity, ↓cartilage degradation	40
CIA	Lctb fermentum	↓proinflammatory cytokines, ↓T-cell proliferation, ↓ IL-10	↓disease activity, ↓cartilage degradation	42
CIA	Lctb delbrueckii	↓proinflammatory cytokines, ↓T-cell proliferation, ↓ IL-10	↓disease activity, ↓cartilage degradation	42
AA	LGG	inflammation	↓ disease activity	55
AA	Enterococcus faecium	disease intensity	↓ disease activity	38
CIA	Lctb bulgaricus	inflammation	↓ disease activity	42

Abbreviations: Lctb: lactobacillus; Bfdbm: bifidobacterium; LcS: Lctb casei Shirota; BbY: Bfdbm breve strain Yakult; Lacto-mix: Lctb paracasei, Lctb plantarum, Lctb delbrueckii; LGG: Lctb GG; VSL#3: a mixture of four species of lactobacilli, three species of bifidobacteria and Streptococcus thermophilus; DSS: dextran sulfate sodium colitis; EAE: experimental autoimmune encephalomyelitis; CIA: collagen induced arthritis; AA: adjuvant arthritis; T1D: insulin-dependent Diabetes Mellitus; CII: Type II collagen; ↓: decreased in severity of disease; ↑: increased in severity of disease; Ø: no effect on severity of disease.

Table 1. Probiotic effects in animal experimental autoimmune disease models are shown.

Disease	Probiotics	Assessment	Outcome	Ref.
Human Clinical Arthritis Trials				
RA	LGG	clinical/biochemical parameters, ↓proinflammatory cytokines	↓ disease activity	43,44
RA	Bacillus coagulans	inflammation	↓ disease activity	45
RA	Living / vegan food	health assessment questionnaire	↓ disease activity	46
Spondyloarthritis	Combination	clinical/biochemical parameters	Ø disease activity	47
Human Clinical T1D Trials				
T1D	Various	autoantibodies	Ø disease activity	53
Human Clinical Inflammatory Bowel Disease Trials				
Pouchitis	VSL#3	inflammation	↓ disease activity	68,70,71
Pouchitis	LGG	inflammation	↓ disease activity	69,72,73
Active UC	E. coli Nissle 1917	inflammation, induction of remission	↓ disease activity	75,76
Active UC	VSL#3	inflammation, induction of remission	↓ disease activity	68,70,71
Active UC	BbY	endoscopic and histological scores	↓ disease activity	77,78
Active UC	LGG	induction of remission	Ø disease activity	69,72,73
UC remission	VSL#3	maintenance of remission	↓ disease activity	79
UC remission	LGG	maintenance of remission	Ø disease activity	76,80
UC remission	Bfdbm breve / bifidum Lctb acidophilus	maintenance of remission	↓ disease activity	78
Active CD	LGG	inducing remission	Ø disease activity	81,82
Active CD	E. coli Nissle 1917	inducing remission	Ø disease activity	81
CD remission	S. boulardii	maintenance of remission	↓ disease activity	83
CD remission	LGG	maintenance of remission	Ø disease activity	82,84,85
CD remission	Lctb johnsonii	maintaining surgically induced remission	↓ disease activity	86,87
CD remission	VSL#3	maintaining surgically induced remission	↓ disease activity	88

Celiac disease	Lctb sanfranciscensis	proteolytic activity	↓ disease activity	89
Celiac disease	Lctb plantarum	proteolytic activity	↓ disease activity	89
Celiac disease	VSL#3	proteolytic activity	↓ disease activity	90
Celiac disease	Bfdbm lactis	proteolytic activity	↓ disease activity	91
Human Clinical Multiple Sclerosis Trials				
Multiple Sclerosis	Various	dysbiosis	↓ disease activity	59

Abbreviations: Bfdbm: bifidobacterium; Lctb: lactobacillus; BbY: Bfdbm breve strain Yakult; LGG: Lctb GG; VSL#3: a mixture of four species of lactobacilli, three species of bifidobacteria and Streptococcus thermophilus; CD: Crohn`s disease; UC: ulcerative colitis; RA: rheumatoid arthritis; T1D: insulin-dependent diabetes mellitus; ↓: decreased in severity of disease; ↑: increased in severity of disease; Ø: no effect on severity of disease.

Table 2. Probiotic effects in human clinical autoimmune disease trials are shown.

8.1 la-probiotic effect in animal experimental arthritis models

Changes in the normal gastrointestinal microflora and dysregulation of the mucosal immune response to these pathogens may contribute to the development of ADs such as rheumatoid arthritis (RA). This possibility has led investigators to evaluate the efficacy of probiotics for alleviating RA symptoms through modulation of the aberrant inflammatory autoimmune response. Of particular interest are LAB probiotics and their immunomodulating and anti-inflammatory effects, which have been shown to lessen the symptoms of arthritis. LAB have been shown to significantly downregulate proinflammatory cytokines (eg, IFN-γ, IL-12, TNF-α) without altering regulatory cytokines (eg, IL-10, TGF-β) to cause anti-inflammatory effects alleviating RA symptoms [37].

Adjuvant arthritis (AA) is a classic murine model for RA, which has been considered a prototype of Th1 disorders. Feeding dairy products fermented with lactobacilli, especially LGG, to rats with AA had a noticeable beneficial effect, surpassing even the effect of oral *Lctb* GG (LGG) alone. There was a statistically significant decrease in inflammation histologically over one month in rats fed yogurt containing LGG compared with rats fed plain yogurt or milk. Ingestion of live or heat-killed human LGG had the same clinical beneficial effect. The authors concluded that the LGG, especially in the form of fermented yogurt, apparently exert both preventive and therapeutic effects on the T-cell-dependent experimental arthritis [37]. Accordingly, AA rats treated in combination with methotrexate and lyophilized probiotic bacteria *Enterococcus faecium*, enriched with organic selenium, had a significantly greater reduction in disease intensity than the methotrexate group [38].

Type II collagen (CII)- induced arthritis (CIA) is considered to be a good model of RA in humans and is often used as a system to evaluate antiinflammatory drugs. An earlier study found that *Lctb casei* reduced the incidence and development of CIA in mice in a dose



dependent manner. Oral administration of *Lactobacillus casei* for 12 weeks reduced signs of CIA including paw swelling, lymphocyte infiltration into the joint, and degradation of cartilage when compared with control animals. *Lactobacillus casei* administration reduced CII-reactive proinflammatory molecules by CD4<sup>+</sup>-T cells. *Lactobacillus casei* administration also reduced CII-reactive Th1-type IgG isotypes IgG2a and IgG2b, while up-regulating immunoregulatory IL-10 levels. These results suggest that oral administration of *Lactobacillus casei* suppresses the CII-reactive effector function of Th1-type cellular and humoral immune responses in arthritic inflammation [39]. Furthermore; in another study CII alone or together with *Lactobacillus casei* was orally administered into rats with CIA, and its effects on the clinical and histopathological aspects of arthritis were investigated. Coadministration of *Lactobacillus casei* with CII more effectively suppressed clinical symptoms, paw swelling, lymphocyte infiltration and destruction of cartilage tissues of experimental arthritis than the rats treated with CII alone. The enhanced therapeutic efficacy was associated with an increase in anti-inflammatory cytokines while decreasing proinflammatory cytokines. Coadministration of *Lactobacillus casei* with CII more effectively suppressed CII-reactive T cell proliferation and the levels of Th1-type IgG isotypes (IgG2a and IgG2b), while up-regulating Foxp3 expression levels and the population of Foxp3<sup>+</sup>/CD4<sup>+</sup> -T cells. This study indicates that *Lactobacillus casei* could potentiate antigen-specific oral tolerance and suppress Th1-type immune responses of arthritic inflammation [40].

Also, oral administration of *Lactobacillus casei* Shirota (*LcS*) into CII-sensitized DBA/1 mice reduced CII-induced IgG2a/2b antibodies in serum and suppressed the CII-induced secretion of IFN- $\gamma$  from splenocytes ex vivo. It has also been shown that *LcS* prevented the onset of CIA in DBA/1 mice [41]. Other studies have reported similar improvements in measures of arthritis after administration of *Lactobacillus fermentum* and *Lactobacillus delbrueckii*. Oral intake of skimmed milk fermented with *Lactobacillus delbrueckii* subsp. *bulgaricus* OLL 1073R-1 prevented CIA in mice. A weaker beneficial effect was noted with fresh skimmed milk and with skimmed milk fermented with another strain of the *Lactobacillus bulgaricus*, OLL 1102 [42].

## 8.2 Ib-probiotic effect in human clinical arthritis trials

A pilot double-blind clinical study evaluated the long-term effects of LGG on symptoms of RA. Twenty-one RA patients were randomized to receive 2 capsules of LGG or placebo twice daily for 12 months. RA activity was reduced in 71% of patients in the LGG group vs 30% of patients in the placebo group. Although there were no statistical differences in clinical or biochemical parameters, more patients in the LGG group reported a greater feeling of well-being [43]. Furthermore, the effects of an orally administered probiotic LGG on sulfasalazine metabolism in individuals with RA were studied in a preliminary study. Although there were also no statistical significant differences in the activity of RA, more subjects in the LGG group reported subjective well being [44].

In another pilot study, RA patients who received *Bacillus coagulans* experienced significant improvement in the pain, greater improvement in patient global assessment, patient self-assessed disability, and reduction in total CRP. *Bacillus coagulans* is a gram-positive, spore-forming, aerobic to microaerophilic LAB bacillus that releases anti-inflammatory molecules or acts indirectly to eradicate organisms in the gut responsible for the inflammatory immune response [45].

A change in the fecal microflora was connected with decreasing activity of RA for one year intervention with living food. 'Living food' is an uncooked vegan diet, which contains no animal products, raffinated substances or added salt. The effects of this diet, *rich in lactobacilli*, in RA patients randomized into diet and control groups were tested. The intervention group experienced subjective relief of rheumatic symptoms during intervention. A return to an omnivorous diet aggravated symptoms. Half of the patients experienced adverse effects (nausea, diarrhoea) during the diet and stopped the experiment prematurely. Nonetheless there was a decrease in the disease activity with lactobacilli-rich and chlorophyll-rich drinks, increase in fibre intake, and no need for gold, methotrexate or steroid medication [46].

In another randomized controlled trial, sixty-three patients with active spondyloarthritis (enteropathic peripheral arthropathies) were randomized to oral probiotic (n = 32) or placebo (n = 31) for 12 weeks. No significant difference was noted between groups in any of the core domains (pain, spinal mobility, patient global, peripheral joint and enthesal scores, stiffness, C-reactive protein, and fatigue) [47].

### 8.3 Ila-probiotic effect in animal experimental T1D models

The NOD mouse and BBDP rat develop a spontaneous form of human T1D that mimics many features of the human disease, thus representing a model for investigating possible therapeutic approaches. A study reported a culture-independent analysis of the bacteria in fecal samples collected from BBDP and BioBreeding diabetes resistant (BBDR) rats. Two genera of bacteria, *Lctb* and *Bfdbm*, emerged as dominant groups negatively correlated with the onset of T1D. Further analysis of the *Lctb* population within these groups established that *Lctb* strains with cinnamoyl esterase activity, *Lctb johnsonii* N6.2 and *Lctb reuteri* TD1 were negatively correlated with T1D development [48]. Taken collectively, these data suggest that the gut and the gut microbiota are potential agents of influence in T1D development. Consistently, recent accumulating data suggest that the gut immune system plays a role in the development of T1D.

Administration of *Lctb johnsonii* N6.2 isolated from BBDR delayed or inhibited the onset of T1D in BBDP rats when administered postweaning. Analysis of the intestinal ileum showed administration of *Lctb johnsonii* induced changes in the native microbiota, host mucosal proteins, and host oxidative stress response. The administration of *Lctb johnsonii* also resulted in higher levels of the tight junction protein claudin. In this study, low expression of pro-inflammatory cytokines IFN- $\gamma$  correlated with the administration of *Lctb johnsonii* N6.2, whereas low expression of TNF- $\alpha$  correlated with overall healthy status [49]. These results indicate that the mechanisms involved in T1D inhibition in BBDP rats may be different from the effect mediated by the probiotic treatment VSL#3.

Previous reports in the NOD model of diabetes have shown that the administration of the probiotic formulation VSL#3 decreased the incidence of T1D through IL-10 immunomodulation and induction of proinflammatory cytokine IFN- $\gamma$ . Early orally administered the probiotic compound VSL#3 induced immunomodulation by a reduction in insulinitis severity and a decreased rate of  $\beta$ -cell destruction in NOD mice. Prevention was associated with an increased production of IL-10 from Peyer's patches and the spleen and

with increased IL-10 expression in the pancreas, where IL-10-positive islet-infiltrating mononuclear cells were detected [50].

Oral feeding of *Lactobacillus casei* to young NOD mice inhibited the occurrence of T1D, prevented the disappearance of insulin-secreting  $\beta$ -cells, and regulated the host immune system response, as reflected by lower IFN- $\gamma$  and higher IL-2 production [51]. From the age of 4 wk, female NOD mice were fed a diet containing LcS, and the onset of diabetes was recorded thereafter. The incidence of diabetes in the control group was significantly higher than that in the LcS-treated group, and pathological analysis of the LcS-treated group revealed strong inhibition of the disappearance of insulin-secreting  $\beta$ -cells in Langerhans islets. Moreover, the proportion of CD8<sup>+</sup>-T cells among spleen cells was decreased in the LcS treated group, suggesting the inhibition of autoreactive T cells. It is postulated that LcS may alter the imbalance of Th1/Th2 cytokine production, which is thought to be the cause of the onset of T1D [13,51].

#### 8.4 IIb-probiotic effect in human clinical T1D trials

The feature of immune-mediated T1D is T cell-mediated destruction of the insulin-producing  $\beta$ -cell in the islets, which results from an imbalance between disease promoting factors and protective elements. The particular mechanisms of  $\beta$ -cell destruction leading to diabetes remain still unclear [52]. A pilot study of PRODIA (probiotics for the prevention of  $\beta$ -cell autoimmunity in children at genetic risk of T1D) included 200 children with genetic risk for T1D. This study was planned to show whether the use of probiotics during the first 6 months of life is safe and feasible and to determine whether the use of probiotics during the first 6 months of life decreases the appearance of T1D-associated autoantibodies. However, the prevalence of autoantibodies among the study subjects at 6, 12, and 24 months of age was at levels close to the expected and the clinical follow-up did not either indicate problems in the feasibility of the study [53].

#### 8.5 IIIa-probiotic effect in animal EAE models

EAE, which is an experimental model for MS, is assumed to be induced by activation of autoreactive Th1 cells that recognize myelin basic protein (MBP), which causes inflammatory demyelination in the central nervous system. It has been previously demonstrated that effects of probiotics on EAE in mice were strain-dependent, either stimulating or suppressing the clinical symptoms. In a murine EAE model it was shown that the outcome of EAE was dependent upon the cytokine profile induced by different probiotic strains. Strains that induced proinflammatory cytokines in the gut aggravated the cumulative disease burden, whereas strains that induced regulatory cytokines reduced this burden. For instance, LcS and Bfdbm strains induced immunoregulatory cytokines and improved EAE, while *Lactobacillus reuteri* induced proinflammatory cytokines and aggravated EAE thru release of Th1-associated cytokines [32].

LcS was previously reported to increase the duration of clinical symptoms in a rat EAE model [54]. Because experiments involving LcS detected mainly enhancement of innate immune responses and promotion of Th1-mediated immune reactivity. To confirm and further investigate modulation of Th1 responses and development of AD by LcS, the consequences of

oral administration of LcS were assessed in several experiments. And a recent data also showing strain-specific differences on the effect of commercially available probiotic drinks in an EAE rat has been described. In this particular model, these probiotic drinks do not enhance but rather suppress the disease by increasing the production of the regulatory cytokines IL-10 and TGF- $\beta$ , which is consistent with the indications that Tregs are involved in EAE [55].

Furthermore, to evaluate the effects and safety of two probiotic strains, LcS and *Bifidobacterium breve* strain Yakult (BbY) were orally administered to Lewis rats with EAE. Three experimental designs were examined by combining different antigen types and probiotic administration periods: (1) EAE was induced with a homogenate of guinea pig spinal cord as the sensitizing antigen, and LcS was orally administered from one week before this sensitization until the end of the experiment; (2) EAE was induced using guinea pig originated MBP as the sensitizing antigen, and LcS was orally administered from one week before this sensitization to the end of the experiment; (3) EAE was induced using guinea pig MBP as the sensitizing antigen, and the probiotic strains (LcS and BbY) were administered starting in infancy (two weeks old) and continued until the end of the experiment. In experiment 1, oral administration of LcS tended to suppress the development of neurological symptoms. Differences in neurological symptoms between the control group and the administration groups did not reach statistical significance in experiments 2 and 3. As a result, these findings support the notion that neither LcS nor BbY exacerbates AD [56].

Effects of *Bifidobacterium animalis* were evaluated during lactation on autoimmune responses in rodents. In the EAE model, *Bifidobacterium animalis* significantly reduced the duration of clinical symptoms and improved the body weight gain compared with the control group. Hence, animals that receive *Bifidobacterium animalis* recover faster than controls. The mechanisms by which *Bifidobacterium animalis* induced these beneficial effects on EAE are unclear, but do suggest an involvement of Treg cells [57].

The preventive effects of five daily-administered probiotic mixture strains (two strains of *Lactobacillus paracasei*, two strains of *Lactobacillus plantarum* and the traditional yogurt bacterium *Lactobacillus delbrueckii subsp. bulgaricus*) were evaluated comparatively on EAE development in mice. This novel probiotic mixture exerts a therapeutic effect on EAE mediated by Tregs producing IL-10. After a primary screening, three strains, *Lactobacillus paracasei* DSM 13434, *Lactobacillus plantarum* DSM 15312 and *Lactobacillus plantarum* DSM 15313, that efficiently prevented EAE development were chosen for further evaluation. This new mixture of three probiotics is subsequently referred to as "Lacto-mix". The immunosuppressive potential of Lacto-mix strains was associated with induction of Tregs and production of IL-4, IL-10 and TGF- $\beta$ 1 in mesenteric lymph nodes and spleen. Despite a preventive effect on EAE, administration of each individual strain to mice with established EAE was not capable to suppress the disease [55]. In another study, treatment with *Lacto-mix* successfully reversed established EAE and demonstrated a unique synergistic effect of these strains to regulate systemic IL-10 release and induce functional Tregs in, not only intestinal lymph nodes, but also in the periphery and central nervous system of diseased animals [58].

## 8.6 IIb-probiotic effect in human clinical MS trials

Much of the epidemiological data in MS is consistent with a role for diet in its initiation, exacerbations, or progression. Some of the dietary factors contributing to the worsening of



MS include a high animal-fat diet; food allergies/intolerances; and digestive malfunctions, including malabsorption and dysbiosis. Gut malabsorption and dysbiosis can be corrected using probiotics. Although there is no known clinical data on the use of probiotics in MS patients, probiotics might have an indirect effect in MS thru correcting dysbiosis [59].

### 8.7 IVa-probiotic effect in animal experimental IBD models

IBD is a life-long and chronic inflammatory condition of the gastrointestinal tract including the 2 major diseases, Crohn's disease (CD) and UC. A convergence of findings show that intestinal microflora play a central role in the pathogenesis of IBD and thus investigators have pursued studies to seek therapeutic effects of manipulating intestinal microflora. A reduction in microbial burden of gut by public health measures contributes to an immunological imbalance in the intestine, which has been explained by the 'hygiene hypothesis'. The question is posed to determine whether a similar explanation can be proposed for the increased incidence of IBD [9,13-15]. The extension of the hygiene hypothesis to IBD opens new therapeutic perspectives including the revisiting of probiotics and other forms of exposure to bacteria or parasite components.

A number of reports have been published that describe the influence of probiotic consumption on colitis in animal trials. In particular, the IL-10<sup>-/-</sup> (knockout) mouse has been extensively studied. IL-10 knockout mice develop colitis when colonized with a conventional flora but remain disease-free when maintained under germ-free conditions. Schultz et al. colonized IL-10<sup>-/-</sup> mice with *Lctb plantarum* 299v two weeks before transfer from a germ free environment to a specific pathogen-free environment. This resulted in significant attenuation of disease and a significant reduction in mesenteric lymph node IL-12 and IFN- $\gamma$  production [60].

Madsen et al. demonstrated a role for *Lctb reuteri* in prevention of colitis in IL-10<sup>-/-</sup> mice. Neonatal IL-10<sup>-/-</sup> mice were shown to have a decreased concentration of colonic *Lctb* species and an increased concentration of mucosal adherent bacteria. Oral administration of the prebiotic lactulose (shown to increase the levels of *Lctb* species) and rectal swabbing with *Lctb reuteri* restored *Lctb* levels to normal and reduced the number of adherent bacteria within the colon. These effects were associated with the attenuation of colitis [61].

In another placebo-controlled trial the efficacy of *Lctb salivarius* UCC118 and *Bfdbm infantis* 35624 in attenuation of colitis in the IL-10<sup>-/-</sup> mouse model was demonstrated. Further studies examined the effect of *Bfdbm infantis* 35624 on early inflammation in IL-10<sup>-/-</sup> mice and wild-type mice of the same genetic background. Pronounced changes occurred in the Peyer's patch following probiotic consumption, with IFN- $\gamma$  reduced in both wild-type and IL-10<sup>-/-</sup> mice [62].

The oral route of administration may not be required for certain probiotic effects. Reduced inflammatory scores and reduced production of proinflammatory cytokines have been observed in IL-10<sup>-/-</sup> mice that had been injected subcutaneously with *Lctb salivarius* UCC118 [63]. Additionally; in order to enhance the probiotic effect in these murine models, investigators have combined probiotic treatment with prebiotics, antibiotics, immunostimulatory DNA sequences or they have genetically engineered the probiotic strain to secrete antiinflammatory mediators. The prebiotic *inulin* and a combination of the



probiotic organisms *Lactobacillus acidophilus* La-5, *Lactobacillus delbrueckii* subsp. *bulgaricus*, *Bifidobacterium* Bb-12, and *Streptococcus thermophilus* significantly reduced inflammation [64]. The effect was enhanced by combination with metronidazole, suggesting a synergistic effect of the combination of anti- and probiotics in the treatment of experimental colitis [65]. Attenuation of DSS (dextran sulfate sodium) colitis was caused by VSL#3 DNA mediated through TLR-9 signaling. Isolated DNA of *E. coli* strain Nissle 1917 showed an antiinflammatory effect in the DSS model as well. Interestingly, specific immunostimulatory DNA sequences have also been shown to attenuate the production of proinflammatory cytokines in UC patients [66]. Genetically modified probiotics have been tested for their ability to attenuate colitis in the IL-10 knockout model. *Lactococcus lactis* was engineered to secrete biologically active IL-10. A significant reduction in inflammation was observed in both murine models [67].

### 8.8 IVb-probiotic effect in human clinical IBD trials

Studies on the use of probiotics in the treatment of noninfectious inflammatory bowel disorders found that 4 strains of *Lactobacillus* and 1 strain of *Streptococcus* were effective in maintaining remission of UC and reducing the postop recurrence of CD. In the randomized controlled trials, 12 of 16 UC but only 2 of CD trials of probiotic therapy were successful. No superiority of any probiotic was clearly evident, but a multi-agent mixture, VSL3# may be better suited in UC and pouchitis [68]. And studies of probiotics e.g. LGG in CD have been disappointing, and a recent Cochrane systematic review has concluded that their use could not be recommended on the available evidence [69].

## 9. Pouchitis

The most compelling evidence for the use of probiotics in IBD comes from randomised double-blind placebo controlled trials with VSL#3 (a mixture of four species of lactobacilli, three species of bifidobacteria and *Streptococcus thermophilus*) in patients with pouchitis. The efficacy of VSL#3 as a maintenance treatment in 40 patients with chronic relapsing pouchitis after antibiotic-induced remission was assessed. After 4 months fewer relapses were found to occur in the intervention group than in the control group. Moreover, all patients were subsequently found to relapse 3 months after cessation of VSL#3. Later, the same group assessed VSL#3 in the primary prevention of pouchitis in 40 patients following surgery. The incidence of pouchitis was found to be reduced and the quality of life improved in the VSL#3-treated group compared with the placebo group [68]. Finally, a further study has confirmed the effectiveness of VSL#3 as maintenance therapy in patients with recurrent or chronic pouchitis [70]. In contrast, Shen et al. have reported no significant benefit of VSL#3 in maintaining antibiotic-induced remission in 31 patients [71].

Trials of other probiotics in the management of pouchitis have yielded mixed results. One observational study of patients receiving LGG after pouch formation has reported a lower rate of pouchitis than in historical controls [72]. However, Kuisma et al. have found no difference in mean pouchitis scores between placebo and LGG-treated groups at the end of a 3-month study period [73]. Finally, a reduction in endoscopic and clinical disease activity associated with an increase in faecal probiotic species has been demonstrated in 51 patients with pouchitis after surgery for UC who consumed fermented milk containing lactobacilli and *bifidobacteria* [74].

## 10. UC

### 10.1 Probiotics to treat active UC

In a study comparing the effect of probiotic *E. coli* Nissle 1917 vs. mesalamine on induction of remission in UC, both groups had similar time to remission, demonstrating equal efficacy of treatments. Consistently, several controlled trials have demonstrated that *E. coli* Nissle 1917 has similar efficacy to conventional mesalazine treatment with fewer side effects [75]. Efficacy of direct delivery of the probiotic to the colon with *E. coli* Nissle 1917 enemas in left-sided UC has been demonstrated [76].

In an open-label trial, VSL#3 was added to current regimen for patients who had failed to respond to conventional therapy for active UC. Addition of VSL#3 for 6 weeks led to either remission or response in 77% of patients as measured by the disease activity index [68].

Active UC was treated with fermented milk including *BbY*, *Bfdbm* bifidum strain Yakult and an *Lctb* acidophillus strain [77]. A recent clinical trial demonstrated that treatment of patients with *Bfdbm* fermented milk compared to placebo leads to a significant decrease in a clinical activity index score, as well as a significant decrease in endoscopic and histological scores after 12 weeks of treatment [78].

### 10.2 Probiotics as maintenance therapy in UC

Treatment with VSL#3 to maintain remission in UC was found to be only 4 of 20 patients had experienced relapse at the end of the study [79]. Several studies examining the use of lactobacilli or bifidobacteria as maintenance treatment in UC have demonstrated conflicting results. Ishikawa et al. have demonstrated a reduction in the number of disease exacerbations in a group of Japanese patients receiving fermented milk containing *Bfdbm* *breve*, *Bfdbm* *bifidum* and *Lctb* *acidophilus* compared with placebo. However, this clinical benefit was not found to be associated with an increase in steroid-free remission or endoscopic improvement in disease activity [78]. Another open-label trial showed that for maintenance of remission in UC that LGG alone, or in combination with mesalamine, demonstrated equal efficacy to mesalamine alone [76,80].

## 11. CD

### 11.1 Probiotics to treat active CD

Previous two studies with *E. coli* Nissle 1917 and LGG had evaluated probiotics in active CD patients, but neither study has demonstrated convincing efficacy, in part because of small numbers of patients [81]. A recent double-blinded placebo controlled trial randomized 11 patients with active CD to receive either LGG or placebo. There was no difference in at the rate of inducing remission for 6 months between the two groups [82].

### 11.2 Probiotics to maintain remission in CD

Evidence for use of probiotics as maintenance therapy in CD is not persuasive, with only a couple of studies reporting positive results. A study comparing *S. boulardii*+antibiotic+mesalazine with mesalazine alone has shown fewer relapses in the former group in patients with medically-induced remission of CD [83]. A recent double-

blinded placebo controlled trial randomized 11 patients with active CD to receive either LGG or placebo. There was no difference at the rate of sustaining remission for 6 months between the two groups [82]. Another randomized, double blind study compared LGG vs. placebo in addition to standard maintenance therapy in a group of 75 children. These studies did not find any advantage for LGG compared with placebo in maintaining medically-induced remission [84].

Several clinical studies have been performed to analyze the effects of probiotics on maintaining surgically-induced remission. Three studies using LGG have not confirmed the effectiveness of this probiotic as a maintenance strategy after surgically-induced remission [84,85]. Another clinical trial utilizing treatment with LGG after surgical resection failed to show prevention of early endoscopic recurrence when compared to placebo. One study suggested modest but not significant improvement in recurrence rates of patients after surgical resection of diseased bowel by *Lctb johnsonii* LA1 [86]. However, two randomised double-blind placebo-controlled studies have reported no effect of *Lctb. johnsonii* LA1 in preventing recurrence in CD patients in surgically induced remission [86,87]. Lastly; Campieri et al. have shown benefit of VSL#3 in preventing post-operative recurrence in 40 patients randomised to 3 months of rifaximin followed by 9 months of VSL#3 or to 12 months of mesalazine [88].

## 12. Celiac disease

The only effective treatment for Celiac is a strict adherence to a gluten-free diet throughout the patient's lifetime. Otherwise, wheat gliadin induces severe intestinal symptoms and small-bowel mucosal damage in patients. Gluten-free products are not widely available and are usually more expensive than their gluten-containing counterparts. There is, therefore, an urgent need to develop safe and effective therapeutic alternatives, to develop high-quality gluten-free products and to investigate the potential of the bread making biotechnology following ancient protocols, which include long-time fermentation by selected sourdough LAB. There is a necessity for new biotechnologies using probiotics as starters for sourdough fermentation to investigate their potential to decrease the risk of gluten contamination in gluten-free products.

Thus, 46 strains of sourdough LAB were screened for proteolytic activity and acidification rate in gluten-free flours. The sourdough cultures consisted of *Lctb sanfranciscensis* and *plantarum* were selected and used for the manufacture of gluten-free bread [89]. Moreover, proteolytic activity by probiotic VSL#3 was also found to have an importance during food processing to produce predigested and tolerated gliadins for increasing the palatability of gluten-free products [90]. In addition; *Bfdbm lactis* was found to inhibit the toxic effects of gliadin in intestinal cell culture conditions [91].

## 13. Conflicting results and reasons of failure in human AD clinical trials

Although human clinical trials for therapeutic probiotic use in AD have been somewhat disappointing, human trials are also performed unsatisfactorily. Firstly, one of the main reasons for this failure is that the topic is becoming currently popular and further studies need to be done. For instance: although arthritis trials both in human and animal are partly successful, there is no still enough clinical data on the use of probiotics in MS and T1D patients.

Secondly; since human is a more complex organism than cell cultures and animals, performing a research in human is very difficult. As expected, most of the hopeful data firstly have come from in vitro cell culture studies and experimental animal models.

Thirdly, there are also difficulties of recognizing mechanisms implicated in ADs. As mentioned upper part of this review; there at least several hypotheses for autoimmunity development and there a lot need to be further clarified. Thus, it is very difficult to decide what kind of probiotic strain would be helpful.

Fourthly, it is very hard to measure net effect of probiotic since the effect of probiotic use is specifically dependent upon strain. Consequently, there is also a large amount of conflicting data on the probiotic use in ADs.

Fifthly, there is also fear from possible side effects of probiotics. As mentioned above, the fact that certain probiotics are known to stimulate Th1 immunity, which might be an additional safety issue. Excessive immunostimulation might aggravate or induce Th1-mediated immune responses, e.g. ADs.

#### **14. Expert commentary (Conclusion)**

As mentioned above, there is a large amount of conflicting data on the preventive/therapeutic effects of probiotics in ADs. Results from metaanalyses and systematic reviews that combine results of studies from different types of probiotics to examine the effects in any disease should be interpreted with caution. There are also difficulties of recognizing etiology and pathogenesis of ADs from RA to IBD in which have many mechanisms involved. Similarly, with various strains, especially LcS, stimulation of Th1-mediated immune responses has been described. Additionally, if probiotics are used in patients with ADs for any reason –therapy or prevention- cautionary approach ought to be taken. Thus, probiotics cannot be recommended generally for primary prevention of ADs. Any probiotics should not be used especially in immune-compromised children; even they have at risk for ADs. Finally, there is insufficient but fairly promising evidence to recommend the addition of probiotics to foods for prevention and treatment of ADs.

##### **14.1 Five-year view**

Involvement of commensal enteric microflora and its components with strong immunoactivating properties in etiopathogenetic mechanism of multifactorial diseases, including IBD, T1D, RA, and allergy has been recently suggested. Regulation of intestinal microflora composition (e.g. by probiotics) offers the possibility to influence the development of mucosal and systemic immunity as well as it can play a role also in prevention and treatment of some ADs. Progress has been made by the identification of receptors and pathways through which gut microbes influence development of the immune system. Such mechanistic data have moved a field that was once regarded as being on the scientific fringe to the mainstream, and support increased funding to advance this promising area of research in the hope that it might deliver the long awaited answer of how to safely prevent ADs.

Better understanding of the effects of different probiotic strains and a deeper insight into the mechanisms of the heterogeneous manifestations of AD are needed for the validation of specific strains carrying anti-autoimmune potential. Therefore, research activities are

currently focusing on identification of specific probiotic strains with immunomodulatory potential and on how dietary content interacts with the most efficacious probiotic strains. Moreover, the selection of the most beneficial probiotic strain, the dose, and the timing of supplementation still need to be determined. Further studies should also clarify if any susceptible groups of ADs exist and how these groups benefit from supplementation with certain probiotic strains.

Some studies in the management of ADs suggest that therapeutic benefit requires a combination of probiotic species (as with VSL#3 or Lacto-mix) or that the component(s) responsible for the anti-inflammatory effect in combination preparations have specific properties that monotherapy probiotics do not. This concept also supports the use of prebiotics that increase concentrations of several commensal immunoregulatory bacteria. Prebiotic use was shown to be associated with a reduction in the faecal concentration of *Bacteroides fragilis*, but had no effect on lactobacilli or bifidobacteria. Genetically modified probiotics will be tested for their ability to attenuate ADs thru secreting regulatory cytokines in experimental models as well. In near future, the researchers will look for more appropriate combinations of probiotic species or modified probiotics with/without prebiotic and test them in human/rodent AD models.

Additionally, side effects are very low and they might not be nonexistent, as shown in a set of patients with different diseases. However, probiotics should not be considered as totally harmless, particularly in the immunodeficient host, and more safety studies are needed. As imagined, probiotics may have unpredictable behaviour like all microorganisms, such as unanticipated gene expression in nonnative host environment, or acquired mutations occurring spontaneously via bacterial DNA-transfer mechanisms. Certain probiotics are known to stimulate Th1 immunity, which has been suggested as one of the mechanisms by which they can suppress Th2-mediated allergic diseases. However, this presumed excessive immunostimulation might aggravate or induce Th1-mediated immune responses and diseases such as T1D, MS; and it might cause an additional safety issue.

Consequence of over-activation of the immune system by probiotics in hosts with immune dysfunctions, such as individuals genetically predisposed to autoimmunity, has raised some concerns too. With respect to the association between bacterial antigens and autoimmune responses and the adjuvant activity of LAB strains, the involvement of LAB in the pathogenesis of some models of autoimmunity in experimental animals and possibly in humans has been suggested. Thus, from a safety point of view, the potential of probiotic bacteria (especially the immunostimulatory strains), to induce destructive inflammation or autoimmunity needs to be investigated. For instance, it has been experimentally demonstrated that *Lctb casei* cell wall components (given intraperitoneally) are able to induce cardioangitis (an autoimmunity-associated heart disease) in mice [92].

## 14.2 Key issues

- Since conclusions on probiotics are limited to specific strains and models, they should not be generalized [32,54,55].
- Probiotics should not be considered as completely harmless, particularly in the immunodeficient host, and more safety studies are needed [54,92].
- Physiological use (normal route, normal dose, normal growth phase, specific strain or substrain/species) is studied in all cases, so as not to overwhelm (high dose) or circumvent natural immune processing [54,92].



- Do probiotics really induce/exacerbate ADs? LGG and others have specific dose- and duration- dependent immunomodulatory effects on the proliferation of B-/T-lymphocytes. Some mice orally fed lactobacilli were demonstrated to have an increased Th1 cytokine production. And this type of immunomodulatory mechanism might exacerbate Th1-dependent ADs [32,54,55,92].
- Th1-mediated immune response stimulation also seems to be dependent on type of disease model as well as probiotic strain. In SJL mice with EAE showed that different lactobacilli strains could enhance or inhibit development of ADs [32,54]. And some immunostimulatory probiotics do not always seem to induce autoimmune responses in models that have the genetic potential to develop autoimmunity. Such as *Lactobacillus rhamnosus* HN001 and *Bifidobacterium lactis* HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis [93].
- The researchers ought to look for more appropriate and safe combinations of probiotic species (as with VSL#3 or Lacto-mix) or modified probiotics with/without prebiotic and test them in human/rodent AD models [55].
- Research activities are currently focusing on identification of specific probiotic strains with immunomodulatory potential and on how dietary content interacts with the most efficacious probiotic strains. Further studies should be made for the identification of receptors and pathways through which gut microbes influence development of the immune system.

## 15. References

- [1] Özdemir Ö. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. *Clin. Exp. Immunol.* 160, 295–304 (2010).
- [2] Tlaskalová-Hogenová H, Stepánková R, Hudcovic T et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. *Immunol. Lett.* 93(2-3), 97-108 (2004).
- [3] Billmann-Born S, Till A, Arlt A et al. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC. *J. Immunol.* 186(7), 4027-4038 (2011).
- [4] Walsh KP, Brady MT, Finlay CM, et al. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. *J. Immunol.* 183(3), 1577-1586 (2009).
- [5] Sgouroudis E, Kornete M, Piccirillo CA. IL-2 production by dendritic cells promotes Foxp3(+) regulatory T-cell expansion in autoimmune-resistant NOD congenic mice. *Autoimmunity.* 44(5), 406-14 (2011). doi: 10.3109/08916934.2010.536795.
- [6] Schwartz RH. Natural regulatory T cells and self-tolerance. *Nat. Immunol.* 6, 327–330 (2005).
- [7] Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. *Clin. Exp. Immunol.* 160 (1), 1–9 (2010).
- [8] Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N. Engl. J. Med.* 347, 911–920 (2002).
- [9] Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? *Curr. Opin. Gastroenterol.* 20(6), 560-564 (2004).
- [10] Bach JF. Protective role of infections and vaccinations on autoimmune diseases. *J. Autoimmun.* 16(3), 347-353 (2001).

- [11] Singh B, Rabinovitch A. Influence of microbial agents on the development and prevention of autoimmune diabetes. *Autoimmunity*. 15(3), 209-213 (1993).
- [12] Brugman S, Klatter FA, Visser JT et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding -prone rat. Is the gut flora involved in the development of type 1 diabetes? *Diabetologia*. 49(9), 2105-2108 (2006).
- [13] Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal microflora: probiotics and autoimmunity. *J. Nutr.* 137(3 Suppl 2), 798S-802S (2007).
- [14] Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat. Clin. Pract. Gastroenterol. Hepatol.* 2(9), 416-422 (2005).
- [15] Vaarala O, Atkinson MA, Neu J. The "Perfect Storm" for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes*. 57, 2555-2562 (2008).
- [16] Joint FAO/WHO, author. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. October 2001. <http://www.fao.org/ag/agn/Probio/probio.htm>.
- [17] Lilly DM, Stillwell RH. Probiotics: Growth-promoting factors produced by microorganisms. *Science*. 147, 747-748 (1965).
- [18] Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G. Yogurt containing probiotic *Lactobacillus rhamnosus* GR-1 and *L. reuteri* RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. *J. Clin. Gastroenterol.* 42(3), 239-243 (2008).
- [19] Al-Mendalawi MD, Heydarian F. Comparison between traditional yogurt and probiotic yogurt in non-inflammatory acute gastroenteritis. *Saudi Med. J.* 31(9), 1071-1072 (2010).
- [20] Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. *Clin. Exp. Immunol.* 149(3), 470-479 (2007).
- [21] Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. Should yoghurt cultures be considered probiotic? *Br. J. Nutr.* 93, 783-786 (2005).
- [22] Hitchins AD, McDonough FEM. Prophylactic and therapeutic aspects of fermented milk. *Am. J. Clin. Nutr.* 49, 675-684 (1989).
- [23] Pashapour N, Iou SG. Evaluation of yogurt effect on acute diarrhea in 6-24-month-old hospitalized infants. *Turk. J. Pediatr.* 48(2), 115-118 (2006).
- [24] Boudraa G, Benbouabdellah M, Hachelaf W, Boisset M, Desjeux JF, Touhami M. Effect of feeding yogurt versus milk in children with acute diarrhea and carbohydrate malabsorption. *J. Pediatr. Gastroenterol. Nutr.* 33(3), 307-313 (2001).
- [25] Sadrzadeh-Yeganeh H, Elmadfa I, Djazayeri A, Jalali M, Heshmat R, Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. *Br. J. Nutr.* 103(12), 1778-1783 (2010).
- [26] Canche-Pool EB, Cortez-Gómez R, Flores-Mejía R et al. Probiotics and autoimmunity: an evolutionary perspective. *Med. Hypotheses*. 70(3), 657-660 (2008).
- [27] Akerblom HK, Virtanen SM, Ilonen J et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. *Diabetologia*. 48(5), 829-837 (2005).
- [28] Petrovsky N. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. *Nat. Rev. Endocrinol.* 6(3), 131-138 (2010).

- [29] Miele E, Pascarella F, Giannetti E et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *Am. J. Gastroenterol.* 104(2), 437-43 (2009).
- [30] Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J. Allergy Clin. Immunol.* 115(6), 1260-1267 (2005).
- [31] So JS, Kwon HK, Lee CG et al. *Lactobacillus casei* suppresses experimental arthritis by down-regulating T helper 1 effector functions. *Mol. Immunol.* 45, 2690-2699 (2008).
- [32] Maassen CB, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. *Vaccine.* 26(17), 2056-2057 (2008).
- [33] Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. *Curr. Opin. Gastroenterol.* 21(4), 426-430 (2005).
- [34] Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. *J. Clin. Gastroenterol.* 42 Suppl 3 Pt 1, S111-115 (2008).
- [35] Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics: effects on immunity. *Am. J. Clin. Nutr.* 73(2 Suppl), 444S-450S (2001).
- [36] Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. *Gastroenterology.* 126, 520-528 (2004).
- [37] Baharav E, Mor F, Halpern M, Weinberger A. *Lactobacillus GG* bacteria ameliorate arthritis in Lewis rats. *J. Nutr.* 134, 1964-1969 (2004).
- [38] Rovinsky J, Svik K, Stancikova M, Istok R, Ebringer L, Ferencik M. Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilized *Enterococcus faecium* enriched with organic selenium. *Folia Microbiol.* 47, 573-578 (2002).
- [39] So JS, Kwon HK, Lee CG et al. *Lactobacillus casei* suppresses experimental arthritis by down-regulating T helper 1 effector functions. *Mol. Immunol.* 45(9), 2690-2699 (2008).
- [40] So JS, Lee CG, Kwon HK et al. *Lactobacillus casei* potentiates induction of oral tolerance in experimental arthritis. *Mol. Immunol.* 46(1), 172-180 (2008).
- [41] Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of *Lactobacillus casei* on type II collagen-induced arthritis in DBA/1 mice. *Life Sciences.* 63, 635-644 (1998).
- [42] Kano H, Kaneko T, Kaminogawa S. Oral intake of *Lactobacillus delbrueckii* subsp. *bulgaricus* OLL1073R-1 prevents collagen-induced arthritis in mice. *J. Food. Prot.* 65, 163-166 (2002).
- [43] Hatakka K, Martio J, Korpela M et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis--a pilot study. *Scand. J. Rheumatol.* 32(4), 211-215 (2003).
- [44] Lee HJ, Waller RD, Stebbings S et al. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. *Int. J. Rheum. Dis.* 13(1), 48-54 (2010).
- [45] Mandel et al. *Bacillus coagulans*: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. *BMC Comp. Altern. Medicine* 10, 1-7 (2010).
- [46] Nenonen MT, Helve TA, Rauma AL, Hanninen OO. Uncooked, lactobacilli-rich, vegan food and rheumatoid arthritis. *Br. J. Rheumatol.* 37, 274-281 (1998).

- [47] Garrett SL, Kennedy LG, Calin A. Patients' perceptions of disease modulation by diet in inflammatory (rheumatoid arthritis/ankylosing spondylitis) and degenerative arthropathies. *Br. J. Rheumatol.* 32(suppl. 2), 43 (1993).
- [48] Scott FW, Cloutier HE, Kleemann R et al. Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. *Diabetes.* 46(4), 589-598 (1997).
- [49] Valladares R, Sankar D, Li N et al. *Lactobacillus johnsonii* N6.2 Mitigates the development of Type 1 diabetes in BB-DP Rats. *PLoS ONE* 5 (5), 10507 (2010).
- [50] Calcinaro F, Dionisi S, Marinaro M et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia.* 48(8), 1565-1575 (2005).
- [51] Matsuzaki T, Nagata Y, Kado S et al. Prevention of onset in an insulin-dependent mellitus model, NOD mice, by oral feeding of *Lactobacillus casei*. *Acta Pathol. Microbiol. Immunol. Scand.* 105, 643-649 (1997).
- [52] Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. *Diabetes Res. Clin. Pract.* 66 Suppl 1, S27-32 (2004).
- [53] Ljungberg M, Korpela R, Ilonen J, Ludvigsson J, Vaarala O. Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes--the PRODIA study. *Ann. N. Y. Acad. Sci.* 1079, 360-364 (2006).
- [54] Maassen CB, van Holten JC, Balk F et al. Orally administered *Lactobacillus* strains differentially affect the direction and efficacy of the immune response. *Vet. Q.* 20 (Suppl. 3), S81-83 (1998).
- [55] Lavasani S, Dzhabazov B, Nouri M et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. *PLoS ONE* 5(2), e9009 (2010).
- [56] Kobayashi T, Kato I, Nanno M et al. Oral administration of probiotic bacteria, *Lactobacillus casei* and *Bifidobacterium breve* does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis. *Immunopharmacol. Immunotoxicol.* 32(1), 116-124 (2010).
- [57] Ezendam J, de Klerk A, Gremmer ER, van Loveren H. Effects of *Bifidobacterium animalis* administered during lactation on allergic and autoimmune responses in rodents. *Clin. Exp. Immunol.* 154(3), 424-431 (2008).
- [58] McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. *J. Immunol.* 175, 3025-3032 (2005).
- [59] Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. *Altern. Med. Rev.* 6(6), 540-566 (2001).
- [60] Schultz M, Veltkamp C, Dieleman LA et al. *Lactobacillus plantarum* 299v in the treatment and prevention of spontaneous colitis in interleukin-10- deficient mice. *Inflamm. Bowel Dis.* 8, 71-80 (2002).
- [61] Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. *Lactobacillus* species prevents colitis in interleukin 10 gene-deficient mice. *Gastroenterology.* 116(5), 1107-1111 (1999).
- [62] Sheil B, MacSharry J, O'Callaghan L et al. Role of interleukin (IL)-10 in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. *Clin. Exp. Immunol.* 144, 273-280 (2006).



- [63] Sheil B, McCarthy J, O'Mahony L et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. *Gut*. 53, 694-700 (2004).
- [64] Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Diseases of the Colon and Rectum* 45, 621-627 (2002).
- [65] Schultz M, Munro K, Tannock GW et al. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. *Clin. Diagn. Lab. Immunol.* 11, 581-587 (2004).
- [66] Rachmilewitz D, Kermeli F, Takabayashi K et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. *Gastroenterology*. 122, 1428-1441 (2002).
- [67] Huibregtse IL, Snoeck V, de Creus A et al. Induction of ovalbumin-specific tolerance by oral administration of *Lactococcus lactis* secreting ovalbumin. *Gastroenterology*. 133(2), 517-528 (2007).
- [68] Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am. J. Gastroenterol.* 100, 1539-1546 (2005).
- [69] Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's Disease. *The Cochrane Database of Systematic Reviews* 2006, issue 4, CD004826. Chichester, West Sussex: John Wiley and Sons Ltd.
- [70] Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 53, 108-114 (2004).
- [71] Shen B, Brzezinski A, Fazio VW et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. *Aliment. Pharmacol. Therapeutics* 22, 721-728 (2005).
- [72] Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain *Lactobacillus rhamnosus* GG. *Diseases of the Colon and Rectum* 47, 876-884 (2004).
- [73] Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of *Lactobacillus rhamnosus* GG on ileal pouch inflammation and microbial flora. *Alimentary Pharmacology and Therapeutics* 17, 509-515 (2003).
- [74] Laake KO, Bjornekleit A, Aamodt G et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configured ileal-pouch-anal-anastomosis in ulcerative colitis. *Scan. J. Gastroenterol.* 40, 43-51 (2005).
- [75] Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet*. 354, 635-639 (1999).
- [76] Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Treatment of mild to moderate acute attacks of distal ulcerative colitis with rectally-administered *E. coli* Nissle 1917: Dose-dependent efficacy. *Gastroenterology* 130 (Suppl. 2), A119 (2006).
- [77] Kato K, Mizuno S, Umesaki Y et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. *Aliment. Pharmacol. Ther.* 20, 1133-1141 (2004).
- [78] Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J. American College Nutrition* 22, 56-63 (2003).



- [79] Venturi A, Gionchetti P, Rizzello F et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Aliment. Pharmacol. Therapeutics* 13, 1103–1108 (1999).
- [80] Zocco MA, dal Verme LZ, Cremonini F et al. Efficacy of *Lactobacillus* GG in maintaining remission of ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 23, 1567–1574 (2006).
- [81] Malchow HA. Crohn's disease and *Escherichia coli*. A new approach in therapy to maintain remission of colonic Crohn's disease? *J. Clin. Gastroenterol* 25, 653–658 (1997).
- [82] Schultz M, Timmer A, Herfarth HH et al. *Lactobacillus* GG in inducing and maintaining remission of Crohn's disease. *BMC Gastroenterol.* 4, 5 (2004).
- [83] Guslandi M, Mezzi G, Sorghi M, Testoni PA. *Saccharomyces boulardii* in maintenance treatment of Crohn's disease. *Digestive Diseases and Sciences* 45, 1462–1464 (2000).
- [84] Bousvaros A, Guandalini S, Baldassano RN et al. A randomized, double-blind trial of *Lactobacillus* GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. *Inflamm. Bowel Dis.* 11, 833–839 (2005).
- [85] Prantera C, Scribano ML, Falasco G, Andreoli A, Luzzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with *Lactobacillus* GG. *Gut.* 51, 405–409 (2002).
- [86] Van Gossum A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (*Lactobacillus johnsonii*, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. *Inflamm. Bowel Dis.* 13, 135–142 (2007).
- [87] Marteau P, Lemann M, Seksik P et al. Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. *Gut.* 55, 842–847 (2006).
- [88] Campieri M, Rizzello F, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study vs mesalamine. *Gastroenterology.* 118, G4179 (2000).
- [89] Di Cagno R, Rizzello CG, De Angelis M et al. Use of selected sourdough strains of *Lactobacillus* for removing gluten and enhancing the nutritional properties of gluten-free bread. *J. Food Prot.* 71(7), 1491–1495 (2008).
- [90] De Angelis M, Rizzello CG, Fasano A et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. *Biochim. Biophys. Acta.* 1762(1), 80–93 (2006).
- [91] Lindfors K, Blomqvist T, Juuti-Uusitalo K et al. Live probiotic *Bifidobacterium lactis* bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. *Clin. Exp. Immunol.* 152(3), 552–558 (2008).
- [92] Okitsu-Negishi S, Nakano I, Suzukim K, Hashira S, Abe T, Yoshino K. The induction of cardioangitis by *Lactobacillus casei* cell wall in mice: I. The cytokine production from murine macrophages by *Lactobacillus casei* cell wall extract. *Clin. Immunol. Immunopathol.* 78, 30–40 (1996).
- [93] Zhou JS, Gill HS. Immunostimulatory probiotic *Lactobacillus rhamnosus* HN001 and *Bifidobacterium lactis* HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. *Int. J. Food Microbiol.* 103(1), 97–104 (2005).



### **Contemporary Pediatrics**

Edited by Dr. Öner Özdemir

ISBN 978-953-51-0154-3

Hard cover, 434 pages

**Publisher** InTech

**Published online** 21, March, 2012

**Published in print edition** March, 2012

Book Contemporary Pediatrics with its 17 chapters will help get us and patients enlightened with the new developments on the contemporary pediatric issues. In this book volume, beyond classical themes, a different approach was made to current pediatric issues and topics. This volume, as understood from its title, describes nutritional infant health and some interesting topics from pediatric subspecialties such as cardiology, hematology and infectious diseases.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Öner Özdemir and Azize Yasemin Göksu-Erol (2012). Probiotics for Autoimmune Diseases: Is There a Benefit?, Contemporary Pediatrics, Dr. Öner Özdemir (Ed.), ISBN: 978-953-51-0154-3, InTech, Available from: <http://www.intechopen.com/books/contemporary-pediatrics/probiotics-for-autoimmune-diseases-is-there-a-benefit>

**INTech**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen